Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1199

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 4
Chunk 1199
---
 partnership with Dr. Emil Kakkis, Mr. Dant and his family were also key advocates speaking to the FDA about the
importance and significant impact of ERT for the treatment of mucopolysaccharidoses. In 2009, Mr. Dant and his family successfully championed
Congress to pass the Ryan Dant Health Care Opportunity Act, H.R. 1441-111.

99

Family
Relationships

There
are no family relationships among any of our directors or executive officers, except that Christer Rosén, our Chief Executive
Officer, is the father of Alexander Rosén, our Chief Administrative Officer.

Involvement
in Certain Legal Proceedings

No
executive officer, member of the board of directors or control person of our Company has been involved in any legal proceeding listed
in Item 401(f) of Regulation S-K in the past 10 years.

Board
Leadership Structure and Board’s Role in Risk Oversight

We
have not separated the positions of Chairman of the Board and Chief Executive Officer. Christer Rosén has served as our Chairman
of the Board of Directors and Chief Executive Officer since January 1, 2016. We believe that combining the positions of Chairman and
Chief Executive Officer allows for focused leadership of our organization which benefits us in our relationships with investors, customers,
suppliers, employees and other constituencies. We believe that consolidating the leadership of the Company under Mr. Rosén is
the appropriate leadership structure for our Company and that any risks inherent in that structure are balanced by the oversight of our
other independent directors on our Board. However, no single leadership model is right for all companies and at all times. The Board
recognizes that depending on the circumstances, other leadership models, such as the appointment of a lead independent director, might
be appropriate. Accordingly, the Board may periodically review its leadership structure. In addition, the Board holds executive sessions
in which only independent directors are present.

Our
Board is generally responsible for the oversight of corporate risk in its review and deliberations relating to our activities. Our principal
source of risk falls into two categories, financial and product commercialization. The audit committee oversees management of financial
risks; our Board regularly reviews information regarding our cash position, liquidity and operations, as well as the risks associated
with each. The Board regularly reviews plans, results and potential risks related to our business. The Board is also expected to oversee
risk management as it relates to our compensation plans